Nuwellis Inc (NUWE)

Feb 20, 2025, 8:00 AM EST - 2 days ago

JACC: Heart Failure Paper Reports Promising Findings of Aquadex Therapy in Updated AVOID-HF Study Analysis

Feb 18, 2025, 4:15 PM EST - 4 days ago

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

Dec 19, 2024, 9:00 AM EST - 2 months ago

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nov 11, 2024, 11:02 AM EST - 3 months ago

Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 8:00 AM EST - 3 months ago

Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 5, 2024, 9:28 AM EST - 3 months ago

Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds

Nov 4, 2024, 8:30 AM EST - 3 months ago

Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid

Nov 1, 2024, 4:15 PM EDT - 4 months ago

Nuwellis Announces Preliminary Results for Third Quarter of 2024

Oct 31, 2024, 8:00 AM EDT - 4 months ago

Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer

Oct 23, 2024, 4:15 PM EDT - 4 months ago

Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024

Sep 25, 2024, 4:15 PM EDT - 5 months ago

Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference

Aug 23, 2024, 9:00 AM EDT - 6 months ago

Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aug 13, 2024, 12:39 PM EDT - 6 months ago

Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 8:00 AM EDT - 6 months ago

Nuwellis, Inc. Announces Second Quarter 2024 Financial Results

Jul 26, 2024, 9:00 AM EDT - 7 months ago

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE™ Therapy at Cincinnati Children's

Jul 24, 2024, 8:02 AM EDT - 7 months ago

Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules

Jul 23, 2024, 4:10 PM EDT - 7 months ago

Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024

Jul 17, 2024, 9:00 AM EDT - 7 months ago

Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children's

Jun 26, 2024, 8:45 AM EDT - 8 months ago

Nuwellis Announces Reverse Stock Split

Jun 25, 2024, 9:00 AM EDT - 8 months ago

Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

Jun 11, 2024, 12:46 PM EDT - 9 months ago

DaVita, Nuwellis Extend Pilot Collaboration for Aquadex

DVA

Jun 6, 2024, 9:00 AM EDT - 9 months ago

Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase

May 14, 2024, 9:00 AM EDT - 10 months ago

Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida

May 9, 2024, 9:00 AM EDT - 10 months ago

Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy

May 7, 2024, 10:29 AM EDT - 10 months ago

Nuwellis, Inc. (NUWE) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:00 AM EDT - 10 months ago

Nuwellis, Inc. Announces First Quarter 2024 Financial Results

Apr 30, 2024, 6:09 PM EDT - 10 months ago

Nuwellis Announces Closing of $2.7 Million Public Offering

Apr 30, 2024, 4:41 PM EDT - 10 months ago

Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024

Apr 26, 2024, 9:17 AM EDT - 10 months ago

Nuwellis Announces Pricing of $2.7 Million Public Offering

Mar 7, 2024, 9:08 AM EST - 1 year ago

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Mar 5, 2024, 12:11 PM EST - 1 year ago

Nuwellis, Inc. (NUWE) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 9:00 AM EST - 1 year ago

Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

Feb 22, 2024, 7:58 AM EST - 1 year ago

Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™

Feb 20, 2024, 5:06 PM EST - 1 year ago

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 20, 2024, 8:42 AM EST - 1 year ago

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Feb 6, 2024, 9:00 AM EST - 1 year ago

New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload

Jan 4, 2024, 3:05 PM EST - 1 year ago

Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nov 7, 2023, 2:06 PM EST - 1 year ago

Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 8:00 AM EST - 1 year ago

Nuwellis, Inc. Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:15 PM EDT - 1 year ago

Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023

Oct 17, 2023, 4:15 PM EDT - 1 year ago

Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Oct 13, 2023, 8:30 AM EDT - 1 year ago

Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Nuwellis Provides Regulatory Update on SeaStar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption

Sep 11, 2023, 4:15 PM EDT - 1 year ago

Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase

Aug 8, 2023, 10:55 AM EDT - 1 year ago

Nuwellis, Inc. (NUWE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 8:15 AM EDT - 1 year ago

Nuwellis, Inc. Announces Second Quarter 2023 Financial Results

Aug 8, 2023, 8:00 AM EDT - 1 year ago

Nuwellis Announces Plan for CFO Transition

Jul 18, 2023, 4:15 PM EDT - 1 year ago

Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023

Jun 13, 2023, 4:15 PM EDT - 1 year ago

Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference